# Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

> **NCT00679783** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 99 (actual)

## Conditions studied

- Ovarian Carcinoma
- Breast Cancer

## Interventions

- **DRUG:** AZD2281

## Key facts

- **NCT ID:** NCT00679783
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-08
- **Primary completion:** 2010-03-26
- **Final completion:** 2022-07-20
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2023-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00679783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00679783, "Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00679783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*